| 16.59 -0.15 (-0.9%) | 04-24 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 21.09  |
1-year : | 22.19 |
| Resists | First : | 18.06 |
Second : | 19 |
| Pivot price | 17.31 |
|||
| Supports | First : | 16.54 |
Second : | 13.76 |
| MAs | MA(5) : | 16.84 |
MA(20) : | 17.55 |
| MA(100) : | 23.81 |
MA(250) : | 24.38 |
|
| MACD | MACD : | -1 |
Signal : | -1.2 |
| %K %D | K(14,3) : | 9.3 |
D(3) : | 13.1 |
| RSI | RSI(14): 28.1 |
|||
| 52-week | High : | 33.99 | Low : | 16.54 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ ACAD ] has closed above bottom band by 13.7%. Bollinger Bands are 61.4% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 16 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 16.87 - 16.96 | 16.96 - 17.07 |
| Low: | 16.28 - 16.39 | 16.39 - 16.5 |
| Close: | 16.39 - 16.57 | 16.57 - 16.78 |
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It's pipeline include, pimavanserin, under phase 3 development for the treatment of Alzheimer's disease psychosis, and negative symptoms of schizophrenia; Trofinetide, a novel synthetic analog, under phase 3 development for the treatment of Rett syndrome; ACP-044, a novel first-in-class orally administered non-opioid analgesic, under phase 2 development for treating acute and chronic pain; and ACP-319, a positive allosteric modulator of the muscarinic receptor, under phase 1 development for treating schizophrenia and cognition in Alzheimer's. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.
Wed, 24 Apr 2024
Acadia Pharmaceuticals to Announce First Quarter Financial Results on May 8, 2024 - Business Wire
Wed, 24 Apr 2024
ACADIA Pharmaceuticals Inc.'s (NASDAQ:ACAD) Price Is Right But Growth Is Lacking - Simply Wall St
Tue, 23 Apr 2024
ACADIA Pharmaceuticals (NASDAQ:ACAD) Sets New 52-Week Low at $16.60 - MarketBeat
Tue, 23 Apr 2024
Zacks Research Analysts Cut Earnings Estimates for ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) - MarketBeat
Mon, 22 Apr 2024
Acadia Pharmaceuticals Announces Trofinetide New Drug Submission for Treatment of Rett Syndrome Has Been ... - Business Wire
Fri, 05 Apr 2024
Oversold Conditions For Acadia Pharmaceuticals (ACAD) - Nasdaq
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Outperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 165 (M) |
| Shares Float | 110 (M) |
| Held by Insiders | 0.4 (%) |
| Held by Institutions | 99.5 (%) |
| Shares Short | 11,200 (K) |
| Shares Short P.Month | 10,810 (K) |
| EPS | -0.38 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 2.61 |
| Profit Margin | -8.5 % |
| Operating Margin | 15.1 % |
| Return on Assets (ttm) | -6.9 % |
| Return on Equity (ttm) | -14.8 % |
| Qtrly Rev. Growth | 69.3 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 4.4 |
| EBITDA (p.s.) | -0.42 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 17 (M) |
| Levered Free Cash Flow | 28 (M) |
| PE Ratio | -44.84 |
| PEG Ratio | -0.1 |
| Price to Book value | 6.33 |
| Price to Sales | 3.76 |
| Price to Cash Flow | 163.68 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|